Can you get rich investing in coronavirus vaccine stocks?

Shares in companies doing coronavirus vaccine and treatment research have rocketed. Is there still time to get in on the big profits?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE: SNG) share price has almost ten-bagged since the beginning of 2020. The company has a potential Covid-19 treatment, known as SNG001, so no surprise there. What’s more, on 18 March the firm released details of its testing plans. It’s not a coronavirus vaccine, but it could possibly be the next best thing.

SNG001 is a based on an existing intravenous antiviral treatment. And Synairgen’s new inhaler version will deliver the drug directly to the lungs, where the coronavirus does its damage. This stuff sounds like it could be a potential lifesaver. As it’s based on an existing well-tested treatment, the trial and approval process could potentially be a lot quicker than for any coronavirus vaccine or treatment being developed from scratch.

The testing started at the end of March. Synairgen CEO Richard Marsde said: “A successful outcome from this trial in Covid-19 patients would be a major breakthrough in the fight against this coronavirus pandemic.” Let’s hope that turns out to be an understatement.

Coronavirus vaccine candidates

In a report last month, IG.com examined 14 companies developing coronavirus vaccines and treatments. Many have seen their share prices soar, but the report points out that they won’t all succeed. The World Health Organization reckons there are more than 50 coronavirus vaccine candidates currently at various stages of development. We might see a small number of those making it through to production and big sales. But how can we decide which those will be? I can’t really see any other viable approach than guesswork.

Most of the companies examined by IG.com are based in the US, unsurprisingly, and one of them sounds like it might have a potential advantage. Inovio Pharmaceuticals already has a vaccine for the MERS coronavirus, and I’d assume that would be a great help. Inovio is hoping to deliver a million doses by the end of the year. But its share price is up only a relatively modest 290% so far this year. Investors seem to be more excited by Synairgen.

UK virus investment

GlaxoSmithKline (LSE: GSK) is in the race too, providing its expertise in adjuvants to companies doing coronavirus vaccine research. I’d never heard of adjuvants before today, but they’re things that can be added to vaccines to boost their effectiveness. They sound like a sort of pharmacological catalyst to me.

GlaxoSmithKline is surely not going to turn into a multibagger any time soon. Though if you’re looking for sure-fire short-term profits, I really can’t help you. But what I do like about GlaxoSmithKline’s involvement is that it makes it something of a ‘picks and shovels’ investment. You know, from the old gold rush days, when no matter who found the shiny stuff, those who sold the tools made nice profits.

Quick growth punt?

Should you take a punt on Synairgen, or any other coronavirus vaccine possibilities? As long as you understand the risk and you’re prepared for a loss if you get the wrong one, I don’t see a problem with investing a small amount of money. But I’d always recommend putting the bulk of your investment cash into long-term quality like GlaxoSmithKline. So in answer to my question in the headline: yes, you might get rich. But you might not. I’d rather go for steady returns compounded over time from a long-term holding in GSK.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »